Scoparone
Based on 7 publication(s) in Google Scholar
Scoparone is isolated from Artemisia capillaris Thunb., has anticoagulant, vasorelaxant antioxidant, anti-inflammatory activities.
For research use only. We do not sell to patients.
- Purity: 99.69%
- CAS No.: 120-08-1
- Formula: C11H10O4
- Molecular Weight:206.19
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Antioxidant Compound Library
HY-L037
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Medicine Food Homology Compound Library
HY-L055
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Scoparone
More- Int J Mol Sci. 2026 Jan 27;27(3):1256. [Abstract]
- ACS Omega. 2025 Aug 21;10(34):39192-39202. [Abstract]
- J Inflamm Res. 2021 Dec 7;14:6601-6618. [Abstract]
- Anim Cells Syst. 2024 Feb 9;28(1):55-65. [Abstract]
- Cell Biochem Biophys. 2025 Feb 18. [Abstract]
- Trop J Pharm Res. Oct, 2022; 21 (10): 2093-2098
- bioRxiv. 2023 Jun 15.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 9
|
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction assay
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction assay
|
[PMID: 20413315] |
| DLD-1 | IC50 |
>100 μM
Compound: 9
|
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction assay
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction assay
|
[PMID: 20413315] |
| HL-60 | IC50 |
1.1 μg/mL
Compound: 6,7-dimethylesculetin
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by XTT assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by XTT assay
|
[PMID: 31784199] |
| Neutrophil | IC50 |
>100 μM
Compound: 14
|
Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry
Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry
|
[PMID: 17822293] |
| Neutrophil | IC50 |
>30 μM
Compound: 6
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge by spectrophotometry
|
[PMID: 19203247] |
| Neutrophil | IC50 |
>30 μM
Compound: 6
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge
|
[PMID: 19203247] |
| Neutrophil | IC50 |
>50 μM
Compound: 10
|
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release
|
[PMID: 18211005] |
| Neutrophil | IC50 |
>50 μM
Compound: aesculetin dimethyl ether
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release
|
[PMID: 18817445] |
| Neutrophil | IC50 |
41.4 μM
Compound: aesculetin dimethyl ether
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced superoxide radical anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced superoxide radical anion generation
|
[PMID: 18817445] |
| Neutrophil | IC50 |
42.86 μM
Compound: 10
|
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced superoxide anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced superoxide anion generation
|
[PMID: 18211005] |
| Neutrophil | IC50 |
8.25 μg/mL
Compound: Aesculetin dimethyl ether
|
Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation
Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation
|
[PMID: 19128011] |
| PC-3 | IC50 |
54.4 μM
Compound: 14
|
Cytotoxicity against human PC3 cells after 3 days by MTT assay
Cytotoxicity against human PC3 cells after 3 days by MTT assay
|
[PMID: 26711890] |
| U-937 | CC50 |
1289 μM
Compound: 7
|
Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay
Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay
|
[PMID: 22925447] |
| U-937 | IC50 |
589.9 μM
Compound: 7
|
Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting
Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting
|
[PMID: 22925447] |
Scoparone (0-0.4 nM; 24-48 hours) produces the most inhibition on PSC proliferation at 0.4 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Chronic Pancreatitis (CP) Rat Models[1]
-
Dosage:30 mg/kg, 60 mg/kg
-
Administration:Oral administration; 30 mg/kg, 60 mg/kg; 4 weeks
-
Result:Protected against pancreatic damage
Chemical Information
-
CAS No. 120-08-1
-
Appearance Solid
-
Molecular Weight 206.19
-
Formula C11H10O4
-
Color Light yellow to yellow
-
SMILES
O=C1C=CC2=CC(OC)=C(OC)C=C2O1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Mechanisms of Antiproliferative Effects of Nobiletin, Scoparone, and Tangeretin Isolated from Citrus reticulata Peel Dichloromethane Extract in Acute Myeloid Leukemia Cells. [Abstract]2026 Jan 27;27(3):1256. PMID: 41683686 -
ACS Omega
2025 Aug 21;10(34):39192-39202. PMID: 40918390 -
J Inflamm Res
Chinese Herbal Medicine Suyin Detoxification Granule Inhibits Pyroptosis and Epithelial-Mesenchymal Transition by Downregulating MAVS/NLRP3 to Alleviate Renal Injury. [Abstract]2021 Dec 7;14:6601-6618. PMID: 34908861 -
Anim Cells Syst
Scoparone attenuates PD-L1 expression in human breast cancer cells by MKP-3 upregulation. [Abstract]2024 Feb 9;28(1):55-65. PMID: 38348341 -
Cell Biochem Biophys
Suyin Detoxification Prescription Regulates the Klotho and ERK/NF-κB Signaling Pathways to Alleviate Renal Injury. [Abstract]2025 Feb 18. PMID: 39966333 -
-
Solvent & Solubility
DMSO : 50 mg/mL (242.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (10.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (10.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.8499 mL | 24.2495 mL | 48.4990 mL | 121.2474 mL |
| 5 mM | 0.9700 mL | 4.8499 mL | 9.6998 mL | 24.2495 mL | |
| 10 mM | 0.4850 mL | 2.4249 mL | 4.8499 mL | 12.1247 mL | |
| 15 mM | 0.3233 mL | 1.6166 mL | 3.2333 mL | 8.0832 mL | |
| 20 mM | 0.2425 mL | 1.2125 mL | 2.4249 mL | 6.0624 mL | |
| 25 mM | 0.1940 mL | 0.9700 mL | 1.9400 mL | 4.8499 mL | |
| 30 mM | 0.1617 mL | 0.8083 mL | 1.6166 mL | 4.0416 mL | |
| 40 mM | 0.1212 mL | 0.6062 mL | 1.2125 mL | 3.0312 mL | |
| 50 mM | 0.0970 mL | 0.4850 mL | 0.9700 mL | 2.4249 mL | |
| 60 mM | 0.0808 mL | 0.4042 mL | 0.8083 mL | 2.0208 mL | |
| 80 mM | 0.0606 mL | 0.3031 mL | 0.6062 mL | 1.5156 mL | |
| 100 mM | 0.0485 mL | 0.2425 mL | 0.4850 mL | 1.2125 mL |
Powered by Bioz